Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evolution of COVID-19 symptoms during the first 9 months after illness onset

View ORCID ProfileElke Wynberg, Hugo van Willigen, Maartje Dijkstra, Anders Boyd, Neeltje A. Kootstra, Joost G. van den Aardweg, Marit J. van Gils, Amy Matser, Marije R. de Wit, Tjalling Leenstra, Godelieve de Bree, Menno D. de Jong, Maria Prins, the RECoVERED Study Group
doi: https://doi.org/10.1101/2021.05.05.21256710
Elke Wynberg
1Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
2Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
(MBBS MSc)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elke Wynberg
  • For correspondence: ewijnberg@ggd.amsterdam.nl
Hugo van Willigen
2Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
3Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
(MD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maartje Dijkstra
1Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
2Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
(MD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anders Boyd
1Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
4Stichting HIV Monitoring, Amsterdam, the Netherlands
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neeltje A. Kootstra
6Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joost G. van den Aardweg
5Department of Pulmonology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
(MD PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marit J. van Gils
3Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Matser
1Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marije R. de Wit
1Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
(MD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tjalling Leenstra
1Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
(MD PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Godelieve de Bree
2Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
(MD PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Menno D. de Jong
3Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
(MD PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Prins
1Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands
2Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
(PhD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Few longitudinal data on COVID-19 symptoms across the full spectrum of disease severity are available. We evaluated symptom onset, severity and recovery up to nine months after illness onset.

Methods The RECoVERED Study is a prospective cohort study based in Amsterdam, the Netherlands. Participants aged>18 years were recruited following SARS-CoV-2 diagnosis via the local Public Health Service and from hospitals. Standardised symptom questionnaires were completed at recruitment, at one week and month after recruitment, and monthly thereafter. Clinical severity was defined according to WHO criteria. Kaplan-Meier methods were used to compare time from illness onset to symptom recovery, by clinical severity. We examined determinants of time to recovery using multivariable Cox proportional hazards models.

Results Between 11 May 2020 and 31 January 2021, 301 COVID-19 patients (167[55%] male) were recruited, of whom 99/301(32.9%) had mild, 140/301(46.5%) moderate, 30/301(10.0%) severe and 32/301(10.6%) critical disease. The proportion of symptomatic participants who reported at least one persistent symptom at 12 weeks after illness onset was greater in those with severe/critical disease (81.7%[95%CI=68.7-89.7%]) compared to those with mild or moderate disease (33.0%[95%CI=23.0-43.3%] and 63.8%[95%CI=54.8-71.5%]). Even at nine months after illness onset, almost half of all participants (42.1%[95%CI=35.6-48.5]) overall continued to report ≥1 symptom. Recovery was slower in participants with BMI≥30kg/m2 (HR 0.51[95%CI=0.30-0.87]) compared to those with BMI<25kg/m2, after adjusting for age, sex and number of comorbidities.

Conclusions COVID-19 symptoms persisted for nine months after illness onset, even in those with mild disease. Obesity was the most important determinant of speed of recovery from symptoms.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The RECoVERED study received funding from ZonMw (project number 10150062010002) and a Research & Development grant (21-14) from the Public Health Service of Amsterdam

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Medical Ethics Examination Committee (METC) of the Amsterdam Medical Centers

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Joint first author

  • ↵** Joint last author

  • ↵*** Listed at the end of the article

Data Availability

Information can be obtained from the corresponding author, Elke Wynberg (ewynberg@ggd.amsterdam.nl)

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 11, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evolution of COVID-19 symptoms during the first 9 months after illness onset
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evolution of COVID-19 symptoms during the first 9 months after illness onset
Elke Wynberg, Hugo van Willigen, Maartje Dijkstra, Anders Boyd, Neeltje A. Kootstra, Joost G. van den Aardweg, Marit J. van Gils, Amy Matser, Marije R. de Wit, Tjalling Leenstra, Godelieve de Bree, Menno D. de Jong, Maria Prins, the RECoVERED Study Group
medRxiv 2021.05.05.21256710; doi: https://doi.org/10.1101/2021.05.05.21256710
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Evolution of COVID-19 symptoms during the first 9 months after illness onset
Elke Wynberg, Hugo van Willigen, Maartje Dijkstra, Anders Boyd, Neeltje A. Kootstra, Joost G. van den Aardweg, Marit J. van Gils, Amy Matser, Marije R. de Wit, Tjalling Leenstra, Godelieve de Bree, Menno D. de Jong, Maria Prins, the RECoVERED Study Group
medRxiv 2021.05.05.21256710; doi: https://doi.org/10.1101/2021.05.05.21256710

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1769)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10812)
  • Forensic Medicine (8)
  • Gastroenterology (594)
  • Genetic and Genomic Medicine (2960)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1933)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12525)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (87)
  • Nephrology (324)
  • Neurology (2808)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1473)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2646)
  • Public and Global Health (5383)
  • Radiology and Imaging (1016)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)